The launch of ‘Mounjaro’, a widely used drug for weight loss and type 2 diabetes, in India has drawn criticism from Rajya Sabha MP Milind Deora, who raised concerns over the growing reliance on Western pharmaceutical solutions.

Taking to social media platform X, Deora remarked, “First, USA floods India with sugary drinks and obesity-inducing lifestyles. Now, they’re pushing ‘weight loss’ drugs to fix the damage.”

While Mounjaro’s arrival addresses the rising obesity and diabetes rates in India, Deora’s comments highlight the need for preventive health measures over pharmaceutical interventions. He advocated for higher taxes on sugary products, restrictions on ads targeting children, and the promotion of intermittent fasting. “India must raise taxes on sugary products, ban ads targeting children & promote intermittent fasting—a proven health solution that works for millions, including me,” he added.

Mounjaro, developed by US-based Eli Lilly, is a once-weekly injectable drug that activates two key hormones, GIP and GLP-1, to regulate blood sugar and control appetite. It is prescribed for individuals with a BMI of 27 or higher, alongside diet and exercise.

The drug is priced at ₹14,000 per month for the lowest dose (2.5 mg), with single-dose vials also available in higher strengths.

Clinical studies show Mounjaro’s effectiveness in weight loss. A trial involving 2,539 adults with obesity found that those on the highest dose (15 mg) lost an average of 21.8 kg over 72 weeks, while those on the lowest dose (5 mg) lost 15.4 kg.

Winselow Tucker, President and GM of Lilly India, has said, “The dual burden of obesity and type 2 diabetes is a major public health challenge. Mounjaro’s launch reflects our commitment to a healthier nation.”